VBIZF (Viva Biotech Holdings) LT-Debt-to-Total-Asset : 0.13 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Viva Biotech Holdings's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.13.

Viva Biotech Holdings's long-term debt to total assets ratio increased from Dec. 2022 (0.11) to Dec. 2023 (0.13). It may suggest that Viva Biotech Holdings is progressively becoming more dependent on debt to grow their business.

Viva Biotech Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for Viva Biotech Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings LT-Debt-to-Total-Asset Chart

Viva Biotech Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.34

0.30

0.11

0.13

Viva Biotech Holdings Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial										0.29	0.11	0.08	0.13	-

Viva Biotech Holdings LT-Debt-to-Total-Asset Calculation

Viva Biotech Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	133.158	/	1043.376
	=	0.13

Viva Biotech Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	133.158	/	1043.376
	=	0.13

Viva Biotech Holdings (OTCPK:VBIZF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Viva Biotech Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Viva Biotech Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (OTCPK:VBIZF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

01873:Hong Kong VB0:Germany

Address

735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318

Website

https://www.vivabiotech.com

Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation (CDMO) and commercialisation services segment include contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates, and formulations. Geographically, the company generates a majority of its revenue from the United States of America, and the rest from the European Union, Chinese Mainland, Africa, and other regions.